Mechanisms whereby deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi
Introduction
Deep brain stimulation (DBS) is a clinical procedure whereby electrical current is passed through surgically implanted electrodes in the brain. Over the last decade, DBS applied to the subthalamic nucleus (STN) or internal globus pallidus (GPi) has been successfully used to treat several movement disorders (Lyons, 2011; Troster, 2009) , including treatment-resistant tardive dyskinesia (TD). TD is a disorder induced by chronic therapy with classical antipsychotic drugs (Damier et al., 2007; Capelle et al., 2010) , which is characterized by abnormal, involuntary movements of the head, neck, face and jaw, which can persist for a prolonged time after medication withdrawal (Casey, 1985 (Casey, , 2004 . While the GPi is the most common DBS target in cases of TD, the STN has also been shown to alleviate motor symptoms associated with chronic antipsychotic use (Zhang et al., 2006; Sun et al., 2007) .
In rats, chronic HAL treatment leads to a syndrome of vacuous chewing movements (VCMs), which are considered analogous to human TD (Turrone et al., 2002) . We have previously shown that DBS of the STN or entopeduncular nucleus (EPN, the rodent homolog of the GPi) effectively suppresses HAL-induced VCMs . However, despite its widespread clinical application in movement disorders, the mechanisms underlying the antidyskinetic effects of DBS remain largely unknown. We have shown that STN-and EPN-DBS influence activity in a variety of brain regions at sites distal from the stimulation target (Creed et al., 2012) , an observation that has also been made in the clinic (Su et al., 2001; Schulte et al., 2006; Damier et al., 2007) . DBS also effects several neurotransmitter systems (Lee et al., 2006; Covey and Garris, 2009; Navailles et al., 2010; Feuerstein et al., 2011; Sgambato-Faure and Cenci, 2012) .
Several lines of evidence implicate the serotonin (5-HT) system in the symptoms of TD and in the effects of STN-DBS. 5-HT provides extensive innervation to the basal ganglia where it mod-ulates dopamine neurotransmission (Alex and Pehek, 2007; Di Matteo et al., 2008) . The lower incidence of TD associated with atypical antipsychotics has been ascribed to their 5-HT 2 receptor antagonism (Meltzer and Nash, 1991; Kapur et al., 1999; Stahl, 1999) , while antagonism of 5-HT 2C receptors suppresses VCMs in rats (Kostrzewa et al., 2007; Creed-Carson et al., 2011) . Moreover, symptoms of TD can be exacerbated by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), which increase synaptic 5-HT levels (Ketai, 1993; D'Souza et al., 1994; Dubovsky and Thomas, 1996; Sandler, 1996; Lauterbach and Shillcutt, 1997; Caley, 1998) . While the effect of EPN-DBS on 5-HT activity has not been examined, STN-DBS has been shown to inhibit firing of serotonergic neurons in the dorsal raphe Hartung et al., 2011) , to decrease 5-HT release in the hippocampus and prefrontal cortex (Navailles et al., 2010) , and to counter the motor effects of 5-HT agonists (Hameleers et al., 2007) .
The objective of the present study was to examine the possible contribution of the serotonin system to the motor effects of DBS in the HAL-induced VCM model of TD.
Materials and Methods
Drug treatment. Male Sprague Dawley rats initially weighing 200 -250 g (Charles River) received either haloperidol decanoate (HAL, Sandoz Canada; 21 mg/kg i.m., N ϭ 68) or sesame oil vehicle (N ϭ 22) once every 3 weeks for 12 weeks (a total of four injections). The decanoate formulation is known to result in constant plasma levels in the 1.1-1.5 mg/kg range and reliably induces progressively increasing levels of VCMs (Turrone et al., 2003) .
Vacuous chewing movement assessments. VCM assessments were conducted once a week in a quiet room, beginning 1 week before the first HAL injection. For each VCM assessment the rat was placed on a flat round surface (26 cm in diameter, 50 cm high) and allowed to acclimate for 2 min. Over the following 2 min a trained observer blind to treatment group recorded the number of VCMs, which were defined as jaw movements in the vertical plane not directed at specific objects accompanied or not by tongue protrusions. Discrete bursts of jaw tremors were counted as one VCM.
VCM assessment in the presence of serotonergic drugs. Each subject was tested after administration of saline or the drug of interest in a randomized cross-over design. Separate groups of rats were administered fluoxetine hydrochloride (Tocris Bioscience) 10 mg/kg, i.p.; (ϩ)-fenfluramine hydrochloride (Sigma-Aldrich) 1 mg/kg, i.p. 1 h before VCM assessments. 2,5-dimethoxy-4-iodoamphetamine (DOI, Sigma-Aldrich) at a dose of 0.1 mg/kg i.p. was administered 30 min before VCM assessments. In a separate group of experiments, 8-hydroxy-DPAT-hydrobromide (8-OH-DPAT, Tocris Bioscience) dissolved in saline was administered via tail-vein injection at a dose of 5 g/kg. VCMs were observed for 4 min after 8-OH-DPAT administration.
Surgery. After 12 weeks of HAL treatment, rats were anesthetized with ketamine/xylazine (100/7.5 mg/kg i.p.) and had polymide-insulated stainless steel monopolar electrodes (250 m in diameter with 0.6 mm of surface exposed) bilaterally implanted into the STN (AP Ϫ3.8 mm; ML ϩ2.5 mm; DV Ϫ8.0) or EPN (AP Ϫ3.6 mm; ML ϩ2.6 mm; DV Ϫ7.8 mm) (Paxinos and Watson, 1986) . Anodes were connected to a bone screw over the somatosensory cortex. Sham surgery controls were anesthetized and had holes drilled into the skull but were not implanted with electrodes.
DBS protocol. Starting 1 week after surgery DBS was applied using a portable stimulator (St Jude Medical, Model 6510) set to deliver 100 A current at 90 s pulse width. Stimulation frequency was set to 130 Hz. These settings were used to approximate a charge density similar to that used in humans, and optimized to achieve optimal anti-dyskinetic effects without inducing other motor side effects, as described previously (Hamani et al., 2010 Creed et al., , 2012 .
Open field tests. After completion of VCM assessments, locomotor activity was assessed in an open field. Rats were placed in automated activity chambers (Med Associates) for a 2 min acclimation period before the onset of DBS (for animals implanted with electrodes). Horizontal activity was then recorded for 15 min during 130 Hz DBS, following which rats were returned to the home cage. Animals without electrodes were also monitored in the activity chamber for 15 min.
In situ hybridization. Hybridization was performed using 35 S-UTP labeled riboprobes prepared by in vitro transcription using consensus promoter sequences for T7 RNA polymerase and cDNA sequences complementary to bases 660 -1043 (according to GenBank # NM_012551). Using the NCBI BLAST Tool, the sequences were checked for homology with the rat genome and found to be specific for their respective transcripts. Probes were diluted to a concentration of 200,000 cpm/l in hybridization solution containing the following: 50% formamide, 35% Denhardt's solution, 10% dextran sulfate, 0.1ϫ SSC, salmon sperm DNA (300 g/ml), yeast tRNA (100 g/ml), and DTT (40 M). Slides were incubated in plastic mailers overnight at 60°C. After hybridization, sections were rinsed in 4ϫ SSC at 60°C, treated in RNase A (20 g/ml) solution at 45°C for 40 min, washed with agitation in decreasing concentrations of SSC containing 5 g/L sodium thiosulfate, dipped in water, dehydrated in 70% ethanol, and air-dried. The slides were exposed to Kodak BioMax film for 6 d at 4°C along with calibrated radioactivity standards. Probe specificity was confirmed by testing labeled sense and scrambled probes, both of which produced no measurable signal on film.
Densitometric analyses were performed with MCID 7.0 software (InterFocus). Before sampling, illumination level was adjusted for every film to ensure consistent background readings across all films. Standard curves obtained from calibrated radioactivity standards were used to convert raw optical density values to radioactivity levels in microcuries per gram of tissue (Ci/g). Basal ganglia regions were analyzed in eight sections per animal, with brain regions defined according to the atlas of Paxinos and Watson (1986) . Readings were first averaged across all sampling windows in a section and then across all sections to produce a final density value for each region for each animal.
Microdialysis. For microdialysis experiments, a guide cannula was implanted into the dorsolateral caudate-putamen (CPu; AP ϩ1.4 mm; ML ϩ2.4 mm; DV Ϫ3.0 mm) during electrode insertion surgery. After 1 week of recovery, a microdialysis probe (MAB4.15.4 Ϫ4 mm membrane, Scientific Products) was inserted into the target and perfused with Ringer's solution at a constant flow rate of 0.7 l/min (microinjection pump, Hamilton). Following an equilibration period of 5 h, dialysate samples were collected every 12 min. Baseline levels were defined as an average of the first five samples collected. DBS was then delivered for 1 h during collection, followed by 96 min of recovery. In some experiments, fluoxetine or fenfluramine were administered 1 h before DBS onset. Samples were analyzed in real time using an Antec Leyden LC110 Alexys HPLC system coupled to a Decade-II electrochemical detection cell (ATS Scientific).
5,7-dihydroxytryptamine lesions. A previously described procedure (Fletcher, 1995) was used with minor modifications. Rats were injected intraperitoneally with 10 mg/kg desipramine-HCl () 30 min before being anesthetized with isoflurane. A 30 gauge needle was lowered into the intended raphe site and 3 g of 5,7-dihydroxytryptamine creatine sulfate (5,7-DHT, Sigma) dissolved in 1% ascorbic acid was injected. Dose refers to the free base. For combined raphe lesions, the needle was lowered to the MRN (AP Ϫ8.0 mm; ML 0 mm; DV Ϫ8.0 mm) and 2 l of 5,7-DHT was infused over 4 min. The needle was left in place for a further 2 min, then raised to the DRN (AP Ϫ8.0 mm; ML 0 mm; DV Ϫ6.0 mm), where the procedure was repeated. For specific lesions of the DRN or MRN, the needle was lowered to the appropriate site and 0.75 l of 5,7-DHT was infused over 2 min; the needle was left in situ for a further 2 min.
Confirmation of serotonin lesions. Serotonin-depleting lesions were confirmed using HPLC to determine concentrations of 5-HT and its metabolite 5-HIAA. In addition, 11 C-DASB binding to the 5-HT transporter was used to assess 5-HT terminal integrity in smaller areas of the same brains. Rats were injected with an overdose of pentobarbital before decapitation and brain extraction. Brains were bisected sagittally offcenter from the midline. Dorsolateral CPu and hippocampus were dissected from the smaller hemisphere, flash-frozen, and stored at Ϫ80°C HPLC, whereas the larger hemisphere was flash-frozen intact for C 11 -DASB autoradiography.
C 11 -DASB autoradiography. Coronal cryostat sections (20 m) were cut and thaw-mounted onto Superfrost slides (Fisher Scientific). Slides were preincubated at 4°C for 20 min in buffer containing 0.05 M Tris, 0.05 M NaCl, and 5 mM KCl, pH 7.4, before being transferred to room temperature buffer containing 4 nM C 11 -DASB freshly synthesized at the CAMH PET Centre for 10 min. Nonspecific binding was determined by displacement with 10 M paroxetine. Slides were rinsed for five 60 s intervals in 4°C buffer, dipped in milliQ water for 10 s, dried with cool air, and immediately exposed to Kodak Biomax film for 24 h.
Densitometric analysis was performed using MCID software (InterFocus). A standard curve relating optical density to known quantities of [ 11 C]DASB (Ci/g) was created. For any subject, the final binding value for any given brain region represented an average of multiple readings on five brain sections. Brain regions were defined according to the atlas of Paxinos and Watson (1986) . Binding values were averaged for each region and then for each subject, and group means were compared independently for each of the regions sampled.
HPLC analyses. Following behavioral tests, lesions were confirmed using HPLC (SP8000 with 25cm ϫ 2.6 mm Spherisorb ODS2 column, Spectra Physics) coupled to an ESA Coulochem II electrochemical detector to measure concentration of 5-HT and its principal metabolite, 5-hydroxindoleacetic acid (5-HIIA) according to a previously published method (Wilson et al., 1994) . Briefly, samples were injected into a six port Rheodyne valve fitted with a 100 l loop. The mobile phase was composed of 0.1 M sodium acetate buffer, pH 3.9, containing 130 mg/L octane sulfonate and 3% methanol, with a flow rate of 1 ml/min. Tissue was weighed and sonicated in 1.0 ml of ice-cold H 2 O, then spiked with 100 l of 1.0 N percholoric acid containing 2 M sodium bisulfite before resonification. Samples were centrifuged at 35,000 ϫ g for 30 min, the supernatant was removed, filtered (0.45 m), and injected into the column. For quantification, every third sample was spiked with a mixture containing standard amounts of each of the compounds being measured.
Verification of electrode placement. Following behavioral tests, rats were deeply anesthetized with sodium pentobarbital and brains were removed, sectioned, postfixed in 10% formalin vapor, and stained with cresyl violet to visualize electrode tracts. Only rats with electrode tips in the STN (Fig. 1 D) or EPN (Fig. 1 E) were included in the analyses.
Statistical analyses. All analyses were performed using SPSS version 15. VCM results were analyzed using repeated-measures ANOVA followed by Tukey's post hoc tests where appropriate. Data from 8-OH-DPAT experiments were analyzed using paired t tests. Raphe lesion data were analyzed with one-way repeated-measures ANOVA. Microdialysis data were analyzed using repeated-measures ANOVA with treatment and target as independent factors.
Results

Effect of DBS on VCMs
As expected, HAL induced VCMs over the course of 12 weeks, the levels of which stabilized by ϳ8 weeks of treatment (Fig. 1 A) . DBS applied to either the STN or EPN significantly decreased VCMs (Fig. 1 B, C) .
Effect of 5,7-DHT lesions on VCMs
To determine the effects of decreasing brain 5-HT on HALinduced VCMs, we performed 5,-7-DHT lesions in HAL-treated rats. VCMs were assessed before surgery and subsequently 1 and 2 weeks after surgery. Repeated-measures ANOVA indicated a significant effect of time on HAL-induced VCMs (F ϭ 8.75, p ϭ 0.002), which was driven by a linear decrease in VCMs over time ( p ϭ 0.001). Two weeks after surgery, VCMs were significantly decreased relative to baseline in the DRN-lesioned animals (Ϫ45%, p ϭ 0.002) and animals that received combined DRNϩMRN lesions (Ϫ37%, p ϭ 0.02). VCMs were not different in MRN-lesioned animals (Ϫ6.4%, p ϭ 0.719) or in subjects with SHAM lesions (Ϫ8.8%, p ϭ 0.171). There was no effect of lesion on VCMs in rats that had not received HAL (data not shown). Lesions were confirmed using HPLC to measure striatal and hippocampal 5-HT content (Fig. 2 A) and by [
11 C]DASB autoradiography (Fig. 2 B) . Relative to sham-lesioned animals, dorsolateral CPu 5-HT levels were significantly lower in rats with lesions to the DRN (Ϫ367%, p Ͻ 0.0001) and combined DRNϩMRN lesions (Ϫ52.5%, p ϭ 0.003). Levels of 5-HT in the hippocampus were significantly decreased in MRN-lesioned (Ϫ44.4%, p ϭ 0.011) and dual-lesioned rats (Ϫ50.5%, p ϭ 0.008). In terms of 
Effect of 8-OH-DPAT on VCMs
To further determine whether decreased 5-HT neuronal activity could affect HAL-induced VCMs, we administered 8-OH-DPAT at a dose previously shown to inhibit serotonergic raphe neuron firing for 8 min after systemic injection (Blier et al., 1989) . Acute treatment with 8-OH-DPAT significantly decreased HALinduced VCMs by 71.1% ( p Ͻ 0.001), whereas saline injections had no effect on VCMs ( p ϭ 0.174) (Fig. 3B) . There was no significant effect of 8-OH-DPAT when rats were pretreated with fluoxetine ( p ϭ 0.670) or fenfluramine ( p ϭ 0.120) pretreatment, so that no significant decreases in VCMs were observed (Fig. 3B) .
Effect of DBS on immediate early gene induction in the raphe nucleus
To determine whether DBS modifies activity of raphe neurons, we measured expression of the immediate early gene zif268. While zif268 expression tended to be higher in HAL-treated rats relative to vehicle controls, this effect did not reach significance in either the DRN ( p ϭ 0.287) or MRN ( p ϭ 0.144). In contrast, DBS applied to the STN significantly decreased zif268 expression in the DRN (VEH: Ϫ 70.9%, p ϭ 0.001; HAL: Ϫ 77.9%, p Ͻ 0.0003) and MRN (VEH: Ϫ 42.5%, p ϭ 0.0245; HAL: Ϫ 35.3%, p ϭ 0.0056). There was no significant effect of EPN-DBS on zif268 expression in either VEH-or HAL-treated rats in either the MRN or DRN (Fig. 4 A, B) .
Effect of DBS on striatal 5-HT release
We performed in vivo microdialysis to determine whether DBS affects 5-HT release in the CPu. Overall, there was a significant effect of DBS target (F ϭ 97.47, p Ͻ 0.001) but not of HALtreatment (F ϭ 2.31, p ϭ 0.143) on 5-HT release in the DL CPu. STN-DBS induced a significant reduction of extracellular 5-HT levels in the DL CPu in both VEH-and HAL-treated rats, whereas EPN-DBS did not alter 5-HT release. The decreased 5-HT release induced by STN-DBS was progressive, and started immediately after DBS onset (VEH: Ϫ 29.0%, p ϭ 0.050; HAL: Ϫ 40.7%, p ϭ 0.017), reaching maximal levels in the sample measured immediately after DBS offset (VEH: Ϫ 74.1%, p Ͻ 0.0001; HAL: MRN (B) , whereas EPN-DBS had no effect. Similarly, STN-DBS significantly decreased 5-HT release in the DL CPu in both HAL-and VEH-treated rats (C). This decrease occurred immediately after DBS onset and persisted for up to 36 min after DBS offset. DBS application is indicated from 60 min to 120 min. Indication of statistical significance is omitted for clarity. EPN-DBS had no effect on 5-HT levels. N ϭ 7-8/group. *p Ͻ 0.05. Ϫ 70.5%, p Ͻ 0.001). 5-HT levels remained decreased 60 min after the stimulation period (VEH: Ϫ 74.1%, p ϭ 0.0002; HAL: Ϫ 59.9% p ϭ 0.0002). In both HAL-and VEH-treated animals undergoing EPN-DBS, 5-HT levels were not significantly different from baseline at any time point (Fig. 4C) .
Effect of serotonergic drug pretreatment on VCM-suppressing effects of DBS
To determine whether the decrease in 5-HT release induced by DBS is necessary for the antidyskinetic effects of DBS, we pharmacologically elevated brain levels of 5-HT by pretreatment with fluoxetine or fenfluramine before the application of DBS. Given the high concentration of 5-HT2 receptors in the DL CPu and their implication in the motor effects of classical antipsychotics (Meltzer and Nash, 1991; Creed-Carson et al., 2011) , we also examined the effect of pretreatment with the nonspecific 5-HT2 agonist DOI on the VCM suppressing effects of DBS.
Fluoxetine
There was a significant effect of HAL treatment (F ϭ 137.51, p Ͻ 0.001) on VCMs, with HAL-treated animals exhibiting higher levels of VCMs than VEH-treated rats. There was also a significant effect of time (F ϭ 25.56, p Ͻ 0.001) and a significant interaction between HAL treatment and time (F ϭ 39.43, p Ͻ 0.001). This interaction was likely due to a decrease in VCMs among HAL-treated rats during DBS, which was not observed in VEH-treated animals. While there was no significant main effect of fluoxetine (F ϭ 0.35, p ϭ 0.554), there was a significant interaction between fluoxetine and time (F ϭ 4.206, p ϭ 0.005) and between fluoxetine, time, and haloperidol (F ϭ 3.81, p ϭ 0.009). Pairwise comparisons revealed that among HAL-treated animals undergoing STN-DBS, fluoxetine pretreatment attenuated the decrease in VCMs induced by DBS. However, this fluoxetine effect only achieved statistical significance at the 60 min time point (Fig. 5A ). There were no significant effects of fluoxetine in VEH-treated animals undergoing STN-DBS (Fig. 5C ) or in any animals receiving EPN-DBS (Fig. 5 B, D) . Fluoxetine had no effect on total distance traveled in the open field (Fig. 6) . At the dosing parameters used, fluoxetine induced a 60% increase in 5-HT peak release and 5-HT levels remained elevated for the duration of DBS. The mean increase across the five time points measured was 32.9% relative to baseline (Fig. 7) .
Fenfluramine
There was a significant effect of time (F ϭ 12.086, p Ͻ 0.0001) on VCM levels, driven by decreased VCMs during DBS. There was no significant effect of fenfluramine pretreatment (F ϭ 1.425, p ϭ 0.250) or interaction between fenfluramine and time (F ϭ 0.810, p ϭ 0.541) (Fig. 5E) . Fenfluramine had no effect on total distance traveled in the open field (Fig. 6) . At the dosing parameters used, fenfluramine induced a 286% increase in 5-HT release and 5-HT levels remained elevated for the duration of DBS. The mean increase across the five time points measured was 279.6% relative to baseline (Fig. 7) .
DOI
There was a significant effect of time (F ϭ 18.04, p Ͻ 0.0001) on VCM levels, driven by decreased VCMs during DBS. There was no significant effect of DOI pretreatment (F ϭ 0.59, p ϭ 0.455) or interaction between DOI and time (F ϭ 0.69, p ϭ 0.612) (Fig.  5F ). DOI had no effect on total distance traveled in the open field (Fig. 6) .
Discussion
Despite its widespread clinical application for the treatment of movement disorders, the mechanisms underlying the therapeutic effects of DBS remain unclear. Altered 5-HT function has been implicated in the pathology of TD, and several effects of DBS on the 5-HT system have been described in preclinical studies. Here we demonstrate that reducing 5-HT neurotransmission, either acutely with 8-OH-DPAT or chronically with 5-7-DHT induced (A, B, E, F ) . After 60 min of STN-DBS, VCM levels were higher after fluoxetine pretreatment than after saline pretreatment (A). There were no differences between saline and fluoxetine pretreatment on VCMs during STN-DBS in VEH-treated rats (C). Fluoxetine pretreatment did not alter the efficacy of EPN-DBS (B, D) . VCM levels were greater during STN-DBS when rats had been pretreated with fenfluramine (E) and DOI (F ), although these differences did not achieve statistical significance. N ϭ 8/group (HALtreated groups) and N ϭ 6/group (VEH-treated groups). depletion of 5-HT, is sufficient to suppress HAL-induced VCMs. However, pharmacological and microdialysis studies showed that decreased brain serotonin function does not play a role in mediating the VCM-suppressing effects of DBS.
The 5-HT system has been implicated in the pathophysiology of TD by several lines of evidence. Briefly, atypical APDs are associated with much lower incidences of TD, which has been ascribed to their 5-HT antagonism or inverse agonism (Meltzer and Nash, 1991; Kapur et al., 1999; Stahl, 1999) . Moreover, SSRI treatment has been shown to exacerbate or precipitate TD in patients concomitantly administered antipsychotics. In clinical and preclinical studies, 5-HT receptor antagonism can reduce VCMs (Kostrzewa et al., 2007; Creed-Carson et al., 2011) . To determine whether reduced 5-HT activity is sufficient to suppress HAL-induced VCMs, we administered the 5-HT 1A inhibitory autoreceptor agonist, 8-OH-DPAT. We observed VCMs during a window in which the dose and concentration of 8-OH-DPAT used has previously been shown to completely inhibit the firing of serotonergic neurons (Blier et al., 1989 ). When we examined VCMs during this period of quiescent 5-HT neurons, we found that VCMs were significantly reduced relative to baseline (Fig.  3B) . Further linking the effects of 8-OH-DPAT to inhibition of 5-HT transmission, the effects of 8-OH-DPAT were abolished by pretreatment with either fenfluramine or fluoxetine. To further test the idea that decreased brain 5-HT may be sufficient to suppress VCMs, we performed selective serotonergic lesions of the raphe nuclei. We report that while MRN lesions had no effect, DRN or combined DRNϩMRN lesions significantly reduced VCMs. This suggests that reducing 5-HT in brain areas innervated by the DRN, which include the basal ganglia, is sufficient to suppress HAL-induced VCMs.
It has been previously shown that STN-DBS inhibits firing of serotonergic neurons in the dorsal raphe Hartung et al., 2011) and decreases 5-HT release in the hippocampus and prefrontal cortex (Navailles et al., 2010) . However, to our knowledge, altered 5-HT release in brain areas implicated in movement control has not been documented. We examined 5-HT release in the CPu because it is an area of the basal ganglia that receives extensive serotonergic innervation and because it is a putative site of action of HAL. Here we show that STN-DBS decreases 5-HT in the DL CPu in both HAL-and VEHtreated rats, whereas EPN-DBS had no effect. The decrease in 5-HT induced by STN-DBS is likely due to decreased activation of raphe neurons, which we assessed by mapping expression of the immediate early gene zif268. In this experiment, STN-but not EPN-DBS decreased activity of DRN and MRN neurons, while EPN-DBS had no effect. Based on the inhibition of the raphe neurons, we can speculate that 5-HT release was decreased in other areas of the basal ganglia as well, since the DRN provides serotonergic innervation to this collection of nuclei (Di Matteo et al., 2008) . 5-HT terminals from the DRN synapse onto dopaminergic and GABAergic neurons in the GP, STN, and SN as well as the CPu (Di Giovanni et al., 2006; Di Matteo et al., 2008) , and modulation of activity of any of these output nuclei or basal ganglia nodes could significantly impact on net basal ganglia output.
Having established that decreasing brain 5-HT content or reducing the firing of dorsal raphe neurons is sufficient to suppress VCMs independently of DBS, and having found that STN-DBS decreases activity of 5-HT neurons and decreases 5-HT release in the CPu, we wanted to determine whether this decrease in 5-HT release and function was a necessary component of the mechanism underlying the VCM-suppressing effects of DBS.
We administered fluoxetine to elevate concentration of extracellular serotonin 1 h before DBS, to determine whether the VCM-suppressing effects of DBS would persist without the decrease in brain serotonin. We found that despite preventing the DBS-induced decrease in brain 5-HT pharmacologically, DBS still suppressed VCMs. This was particularly true in the case of EPN-DBS, where pretreatment with fluoxetine had no effect on VCM levels during DBS. However, in the case of the STN, VCM levels were slightly but significantly higher after pretreatment with fluoxetine than with saline. To further investigate whether this decrease in 5-HT really does contribute to the VCM-suppressing effects of STN-DBS, we used fenfluramine to achieve higher increases in 5-HT levels. In a further attempt to modulate 5-HT, we administered the 5-HT2 antagonist, DOI, which was chosen because of the high concentration of 5-HT2 receptors in the CPu, a target site of action of HAL (Di Giovanni et al., 2006) . 5-TH2 receptors were also of interest because of their abundant postsynaptic distribution in the basal ganglia and because they mediate the modulatory effects of 5-HT on dopamine (Alex and Pehek, 2007; Di Matteo et al., 2008; Di Giovanni et al., 2010) . There was a slight but nonsignificant effect of both fenfluramine and DOI on the VCM-suppressing effects of DBS. Together, these results suggest that preventing the DBS-induced decrease in 5-HT does not interfere with the VCM-suppressing effects of STN-or EPN-DBS.
The effect of STN-DBS on the 5-HT system has been studied in preclinical models, in the context of both motor and cognitive effects (Navailles and De Deurwaerdère, 2012) ; however, to our knowledge, this is the first study to compare the effects of STN-and EPN-DBS on the 5-HT system. Moreover, this is the first study to examine the basal ganglia, and to attempt to elucidate the contribution of decreased 5-HT release to the motor effects of DBS. Clinically, both the STN and GPi have been used effectively to relieve symptoms of treatment-resistant TD and tardive dystonia (Damier et al., 2007; Sun et al., 2007) . Our observation that EPN-DBS suppresses VCMs in this model despite its lack of effect on the 5-HT system further strengthens our conclusion that decreasing 5-HT is not a necessary component of the DBS therapeutic mechanism.
The current findings that preventing 5-HT decreases or that agonism of postsynaptic 5-HT receptors does not interfere with Figure 7 . Effect of serotonergic manipulations of 5-HT release. Pretreatment with either fluoxetine (160% relative to baseline) or fenfluramine (386% relative to baseline) elevated 5-HT release. 5-HT release was significantly higher than baseline at the 72 min time point in fenfluramine-treated rats and at the 108 min time point after fluoxetine treatment. Indication of statistical significance was omitted for clarity. Levels remained elevated relative to baseline (fluoxetine: 132.9%, fenfluramine: 279.6%) for the duration of DBS and up to 60 min after DBS offset.
the motor effects of DBS may have implications for the treatment of psychiatric side effects that may accompany DBS . Our results suggest that treatment with SSRIs or other drugs that elevate brain 5-HT will not likely have adverse effects on motor outcome of DBS.
We have shown that decreasing brain 5-HT content with 5,7-DHT lesions or decreasing activity of serotonergic neurons with the inhibitory autoreceptor agonist 8-OH-DPAT is sufficient to suppress VCMs induced by chronic HAL treatment. We have also demonstrated that STN-DBS decreases 5-HT release in the DL CPu and inhibits neurons in the dorsal and medial raphe nucleus, while EPN-DBS has no effect on 5-HT release or raphe neuron activation. Based on our observation that both STN-and EPN-DBS attenuate VCMs with equal efficacy, despite their differential effects on the 5-HT system, we conclude that decreases in brain 5-HT are not a necessary component of the DBS therapeutic mechanism in a model of TD.
